文献速递心境障碍焦虑、强迫与应激相关障碍精神分裂症与精神病性障碍

精神障碍药物与神经刺激干预随机试验中的安慰剂效应:一项伞状综述

Placebo effects in randomized trials of pharmacological and neurostimulation interventions for mental disorders: An umbrella review.
PubMed 文献 · Mol Psychiatry · 2024-06-24

该伞状综述纳入20项荟萃分析(含1691项随机对照试验、261730例患者),评估精神障碍药物或神经刺激试验中安慰剂效应大小。安慰剂效应在酒精使用障碍、抑郁、不宁腿综合征和广泛性焦虑障碍中较大,在强迫症、原发性失眠和精神分裂症谱系障碍中为小到中等。多数荟萃分析质量评为低。

要点

  • 安慰剂效应在酒精使用障碍(g=0.90)、抑郁(g=1.10)、不宁腿综合征(g=1.41)和广泛性焦虑障碍(d=1.85)中较大。
  • 安慰剂效应在强迫症(d=0.32)、原发性失眠(g=0.35)和精神分裂症谱系障碍(标准化均值变化=0.33)中为小到中等。
  • 多个精神障碍中安慰剂反应较大的相关因素包括发表年份较晚(注意缺陷多动障碍为相反发现)、年龄较小、试验中心更多、样本量更大、基线严重度更高和积极治疗效应量更大。

核心结论

  • 安慰剂效应大小在不同精神障碍间差异显著。
  • 未来研究应探索这种差异的来源。
  • 文献存在重要空白:应激相关障碍、进食障碍、行为成瘾或双相躁狂无符合条件的安慰剂反应系统综述或荟萃分析。

研究设计与样本

  • 研究为伞状综述,基于预注册方案检索Medline、PsycInfo、EMBASE和Web of Knowledge至2022年10月23日。
  • 纳入报告精神药物或神经刺激随机对照试验中安慰剂效应大小的系统综述或荟萃分析。
  • 共纳入20项荟萃分析,汇总1691项随机对照试验,涉及261730例患者。

主要发现

  • 安慰剂效应在酒精使用障碍中较大(g=0.90,95%CI[0.70,1.09])。
  • 安慰剂效应在抑郁中较大(g=1.10,95%CI[1.06,1.15])。
  • 安慰剂效应在不宁腿综合征中较大(g=1.41,95%CI[1.25,1.56])。
  • 安慰剂效应在广泛性焦虑障碍中较大(d=1.85,95%CI[1.61,2.09])。
  • 安慰剂效应在强迫症中为小到中等(d=0.32,95%CI[0.22,0.41]),在原发性失眠中为小到中等(g=0.35,95%CI[0.28,0.42]),在精神分裂症谱系障碍中为小到中等(标准化均值变化=0.33,95%CI[0.22,0.44])。

关键数值与推荐

  • 多个精神障碍中安慰剂反应较大的相关因素包括发表年份较晚(注意缺陷多动障碍为相反发现)、年龄较小、试验中心更多、样本量更大、基线严重度更高和积极治疗效应量更大。
  • 20项荟萃分析中多数(18/20)按AMSTAR-2评为「低」质量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 20项荟萃分析中多数(18/20)按AMSTAR-2评为「低」质量。
  • 文献存在重要空白:应激相关障碍、进食障碍、行为成瘾或双相躁狂无符合条件的系统综述或荟萃分析。
  • 未来研究应探索安慰剂效应大小差异的来源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a growing literature exploring the placebo response within specific mental disorders, but no overarching quantitative synthesis of this research has analyzed evidence across mental disorders. We carried out an umbrella review of meta-analyses of randomized controlled trials (RCTs) of biological treatments (pharmacotherapy or neurostimulation) for mental disorders. We explored whether placebo effect size differs across distinct disorders, and the correlates of increased placebo effects. Based on a pre-registered protocol, we searched Medline, PsycInfo, EMBASE, and Web of Knowledge up to 23.10.2022 for systematic reviews and/or meta-analyses reporting placebo effect sizes in psychopharmacological or neurostimulation RCTs. Twenty meta-analyses, summarising 1,691 RCTs involving 261,730 patients, were included. Placebo effect size varied, and was large in alcohol use disorder (g = 0.90, 95% CI [0.70, 1.09]), depression (g = 1.10, 95% CI [1.06, 1.15]), restless legs syndrome (g = 1.41, 95% CI [1.25, 1.56]), and generalized anxiety disorder (d = 1.85, 95% CI [1.61, 2.09]). Placebo effect size was small-to-medium in obsessive-compulsive disorder (d = 0.32, 95% CI [0.22, 0.41]), primary insomnia (g = 0.35, 95% CI [0.28, 0.42]), and schizophrenia spectrum disorders (standardized mean change = 0.33, 95% CI [0.22, 0.44]). Correlates of larger placebo response in multiple mental disorders included later publication year (opposite finding for ADHD), younger age, more trial sites, larger sample size, increased baseline severity, and larger active treatment effect size. Most (18 of 20) meta-analyses were judged 'low' quality as per AMSTAR-2. Placebo effect sizes varied substantially across mental disorders. Future research should explore the sources of this variation. We identified important gaps in the literature, with no eligible systematic reviews/meta-analyses of placebo response in stress-related disorders, eating disorders, behavioural addictions, or bipolar mania.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Huneke NTM, Amin J, Baldwin DS, et al. Placebo effects in randomized trials of pharmacological and neurostimulation interventions for mental disorders: An umbrella review. Mol Psychiatry. 2024. PMID: 38914807. doi:10.1038/s41380-024-02638-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。